These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70 related articles for article (PubMed ID: 7300510)
21. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235 [TBL] [Abstract][Full Text] [Related]
22. [Effect of a number of preparations on the function of the immune system in experimental influenza in mice]. Ivanova VV; Aksenov OA; Murina EA; Blagoslovenskiĭ GS; Gnilevskaia ZU Vopr Virusol; 1984; 29(5):530-5. PubMed ID: 6516325 [TBL] [Abstract][Full Text] [Related]
23. The immune system provides a strong response to even a low exposure to virus. Powell TJ; Dwyer DW; Morgan T; Hollenbaugh JA; Dutton RW Clin Immunol; 2006 Apr; 119(1):87-94. PubMed ID: 16386960 [TBL] [Abstract][Full Text] [Related]
24. Severe impairment of primary but not memory responses to influenza viral antigens in aged mice: costimulation in vivo partially reverses impaired primary immune responses. Sambhara S; Kurichh A; Miranda R; James O; Underdown B; Klein M; Tartaglia J; Burt D Cell Immunol; 2001 May; 210(1):1-4. PubMed ID: 11485346 [TBL] [Abstract][Full Text] [Related]
25. Beta 2-microglobulin-deficient mice can be protected against influenza A infection by vaccination with vaccinia-influenza recombinants expressing hemagglutinin and neuraminidase. Epstein SL; Misplon JA; Lawson CM; Subbarao EK; Connors M; Murphy BR J Immunol; 1993 Jun; 150(12):5484-93. PubMed ID: 8390536 [TBL] [Abstract][Full Text] [Related]
26. [Use of mouse splenocytes as targets for the analysis of cell cytotoxicity in experimental influenza]. Shidlovskaia NK; Leont'eva GF Vopr Virusol; 1987; 32(2):241-4. PubMed ID: 3604188 [No Abstract] [Full Text] [Related]
27. Kinetic profile of influenza virus infection in three rat strains. Daniels MJ; Selgrade MK; Doerfler D; Gilmour MI Comp Med; 2003 Jun; 53(3):293-8. PubMed ID: 12868575 [TBL] [Abstract][Full Text] [Related]
28. [Characteristics of the damage to immunocompetent organs in experimental slow influenza infection]. Kharitonova AM; Salov VF; Bykovskaia SI; Pereverzev NA; Mirchik EP; Zuev VA Vestn Akad Med Nauk SSSR; 1990; (5):52-8. PubMed ID: 2389605 [TBL] [Abstract][Full Text] [Related]
30. [Viral characteristics and immunological reactions of the body during adaptation of influenza virus type A to mice. I. Viral variability]. Loza-Tulimowska M Med Dosw Mikrobiol; 1984; 36(1):33-44. PubMed ID: 6330473 [No Abstract] [Full Text] [Related]
31. Naive, effector, and memory CD8 T cells in protection against pulmonary influenza virus infection: homing properties rather than initial frequencies are crucial. Cerwenka A; Morgan TM; Dutton RW J Immunol; 1999 Nov; 163(10):5535-43. PubMed ID: 10553081 [TBL] [Abstract][Full Text] [Related]
32. A protective immune response in mice to viral components other than hemagglutinin in a live influenza A virus vaccine model. Horimoto T; Takada A; Iwatsuki-Horimoto K; Kawaoka Y Vaccine; 2004 Jun; 22(17-18):2244-7. PubMed ID: 15149783 [TBL] [Abstract][Full Text] [Related]
33. A serum mannose-binding lectin mediates complement-dependent lysis of influenza virus-infected cells. Reading PC; Hartley CA; Ezekowitz RA; Anders EM Biochem Biophys Res Commun; 1995 Dec; 217(3):1128-36. PubMed ID: 8554567 [TBL] [Abstract][Full Text] [Related]
34. Natural influenza A virus infection of mice elicits strong antibody response to HA2 glycopolypeptide. Kostolanský F; Mucha V; Slováková R; Varecková E Acta Virol; 2002; 46(4):229-36. PubMed ID: 12693859 [TBL] [Abstract][Full Text] [Related]
35. Enhanced antibody and cytokine responses to influenza viral antigens in perforin-deficient mice. Sambhara S; Switzer I; Kurichh A; Miranda R; Urbanczyk L; James O; Underdown B; Klein M; Burt D Cell Immunol; 1998 Jul; 187(1):13-8. PubMed ID: 9681998 [TBL] [Abstract][Full Text] [Related]
36. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses. Du N; Li W; Li Y; Liu S; Sui Y; Qu Z; Wang Y; Du Y; Xu B Vaccine; 2008 Jun; 26(23):2912-8. PubMed ID: 18448208 [TBL] [Abstract][Full Text] [Related]
37. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Fan J; Liang X; Horton MS; Perry HC; Citron MP; Heidecker GJ; Fu TM; Joyce J; Przysiecki CT; Keller PM; Garsky VM; Ionescu R; Rippeon Y; Shi L; Chastain MA; Condra JH; Davies ME; Liao J; Emini EA; Shiver JW Vaccine; 2004 Aug; 22(23-24):2993-3003. PubMed ID: 15297047 [TBL] [Abstract][Full Text] [Related]
38. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Pushko P; Parker M; Ludwig GV; Davis NL; Johnston RE; Smith JF Virology; 1997 Dec; 239(2):389-401. PubMed ID: 9434729 [TBL] [Abstract][Full Text] [Related]
39. [Analysis of the mechanisms of resistance to influenza virus of cells of the immune system]. Poliak RIa; Dubrovina TIa; Leont'eva GF; Smorodintsev AA Dokl Akad Nauk SSSR; 1980; 251(3):725-8. PubMed ID: 7379693 [No Abstract] [Full Text] [Related]